Skip to main content
Addgene

pLKO.1puro-shWillin-B
(Plasmid #40886)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 40886 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pLKO.1 puro
  • Backbone manufacturer
    Addgene 8453
  • Backbone size w/o insert (bp) 7032
  • Total vector size (bp) 7079
  • Vector type
    Mammalian Expression, Lentiviral, RNAi
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    shWillin-B
  • Alt name
    FRMD6
  • gRNA/shRNA sequence
    TTCATTCTCAGTGTGTGCT
  • Species
    H. sapiens (human)
  • Entrez Gene
    FRMD6 (a.k.a. C14orf31, EX1, Willin, c14_5320)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site AgeI (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer pLKO.1 seq
    • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLKO.1puro-shWillin-B was a gift from Paul Reynolds (Addgene plasmid # 40886 ; http://n2t.net/addgene:40886 ; RRID:Addgene_40886)

  • For your References section:

    Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Angus L, Moleirinho S, Herron L, Sinha A, Zhang X, Niestrata M, Dholakia K, Prystowsky MB, Harvey KF, Reynolds PA, Gunn-Moore FJ. Oncogene. 2012 Jan 12;31(2):238-50. doi: 10.1038/onc.2011.224. Epub 2011 Jun 13. 10.1038/onc.2011.224 PubMed 21666719
Related items:
Commonly requested with: